NHL: Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Pathways

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Date of Birth:</th>
<th>Member Number:</th>
<th>Treatment Start Date:</th>
<th>Pathology:</th>
<th>Stage:</th>
<th>Line of Therapy:</th>
<th>Leukemia Stage:</th>
<th>Biomarkers/Characteristics:</th>
<th>ECOG Performance Status:</th>
<th>ICD-10 Code:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>_1st Line  _2nd Line _3rd Line _3rd Line+ _Maint</td>
<td>_NS (No stage) _Recurrent</td>
<td>11q deletion: _Absent _Present</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CD20 Status: _Negative _Positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17p deletion: _Absent _Present</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TP53 status: _Mutation absent _Mutation present</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**First Line of Therapy (1st Line) | With 17p Deletion or TP53 Mutation Present**

___Ibrutinib (Imbruvica)

**First Line of Therapy (1st Line) | Without 17p Deletion or TP53 Mutation Present**

___Ibrutinib (Imbruvica)

___Venetoclax (Venclexta) and obinutuzumab (Gazyva)

**Second and Subsequent Lines of Therapy (2nd Line+) | With 17p Deletion or TP53 Mutation Present**

___Duvelisib (Copiktra)

___Ibrutinib (Imbruvica)

___Idelalisib (Zydelig)

___Idelalisib (Zydelig) and rituximab

___Venetoclax (Venclexta) and rituximab

**Second and Subsequent Lines of Therapy (2nd Line+) | Without 17p Deletion or TP53 Mutation Present**

___Duvelisib (Copiktra)

___Ibrutinib (Imbruvica)

___Idelalisib (Zydelig)

___Idelalisib (Zydelig) and rituximab

___Venetoclax (Venclexta) and rituximab

Primary treatment for CLL should be initiated in accordance with the guidelines established by the Working Group on CLL.

*Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.*